Atherosclerosis Supplements
Volume 10, Issue 5 , Pages 89-94 , 29 December 2009

Treatment of symptomatic HyperLp(a)lipoproteinemia with LDL-apheresis: a multicentre study

  • C. Stefanutti

      Affiliations

    • Dipartimento di Clinica e Terapia Medica, Plasmapheresis Unit, University of Rome “La Sapienza”, Policlinico “Umberto I”, Italy
    • Corresponding Author InformationDepartment of Clinical and Medical Therapy. Plasmapheresis Unit. “La Sapienza”, University of Rome. “Umberto I” Hospital. 155, Viale del Policlinico I-00161 Rome, Italy. Phone: ++39 06 49970578
    • ,
  • G. D'Alessandri

      Affiliations

    • UOC Immunoematologia e Trasfusionale, ASL 3, Pistoia, Italy
    • ,
  • G. Russi

      Affiliations

    • UOC Medicina Trasfusionale e Immunoematologia “Arcispedale S. Maria Nuova”, Reggio Emilia, Italy
    • ,
  • G. De Silvestro

      Affiliations

    • UOC Immunotrasfusionale – Az. Ospedaliera di Padova – University of Padova, Italy
    • ,
  • M.G. Zenti

      Affiliations

    • Divisione di Endocrinologia e Malattie del Metabolismo, Azienda Ospedaliera-Universitaria di Verona, Italy
    • ,
  • P. Marson

      Affiliations

    • UOC Immunotrasfusionale – Az. Ospedaliera di Padova – University of Padova, Italy
    • ,
  • D. Belotherkovsky

      Affiliations

    • Dipartimento di Clinica e Terapia Medica, Plasmapheresis Unit, University of Rome “La Sapienza”, Policlinico “Umberto I”, Italy
    • ,
  • A. Vivenzio

      Affiliations

    • Dipartimento di Clinica e Terapia Medica, Plasmapheresis Unit, University of Rome “La Sapienza”, Policlinico “Umberto I”, Italy
    • ,
  • S. Di Giacomo

      Affiliations

    • Dipartimento di Clinica e Terapia Medica, Plasmapheresis Unit, University of Rome “La Sapienza”, Policlinico “Umberto I”, Italy

References 

  1. Bewu AD , Durrington PN . Lipoprotein (a): structure, properties and possibile involvement in thrombogenesis and atherogenesis . Atherosclerosis . 1990;85:1–14
  2. Dahlén GH , Guyton JR , Atter M , Farmer JA , Kautz JA , Gotto AM . Associations of levels of lipoprotein (a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography . Circulation . 1986;74:758–764
  3. Duriez P , Dallongeville J , Fruchart JC . Lipoprotein(a) as a marker for coronary heart disease . Br J Clin Pract . 1996;77A:54–61
  4. Amstrong VM, Cremer P, Eberle E, Manke A, Schulze F, Wieland H, et al. The association between serum Lp(a) concentration and angiographically assessed coronary atherosclerosis. Dependence on serum LDL levels . Atherosclerosis . 1986;62:249–257
  5. Emerging Risk Factors Collaboration , Erqou S, Kaptoge S, Perry PL, Di Angelantonio E, Thompson A, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality . JAMA . 2009;302:412–423
  6. Kamstrup PR , Tybjaerg-Hansen A , Steffensen R , Nordestgaard BG . Genetically-elevated lipoprotein (a) and increased risk of myocardial infarction . JAMA . 2009;301:2331–2339
  7. Marcovina SM , Koschinsky ML , Albers JJ , Skarlatos S . Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: Recent Advances and Future Directions . Clinical Chemistry . 2003;49(11):1785–1796
  8. Craig WY , Neveux LM , Palomaki GE , Cleveland MM , Haddow JE . Lipoprotein (a) as a risk factor for ischaemic heart disease: metaanalysis of prospective studies . Clin Chem . 1998;44:2301–2306
  9. Danesh J , Collins R , Peto R . Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies . Circulation . 2000;102(10):1082–1085
  10. Dahlén GH , Ekstedt B . The importance of the relation between lipoprotein(a) and lipids for development of atherosclerosis and cardiovascular disease . J. Intern. Med . 2001;250(3):265–267
  11. Keller C . Apheresis in coronary heart disease with elevated Lp(a): a review of Lp(a) as a risk factor and its management . Ther Apher Dial . 2007;11(1):2–8
  12. Crouse JR . New developments in the use of niacin for treatment of hyperlipidemia: new considerations in the use of an old drug . Coron Artery Dis . 1996;7:321–326
  13. Sirtori CR, Calabresi L, Ferrara S, Pazzucconi F, Bondioli A, Baldassarre D, et al. L-Carnitine reduces plasma lipo protein(a) levels in patients with hyper Lp(a) . Nutr Metab Cardiovasc Dis . 2000;10:247–251
  14. Shewmon DA, Stock JL, Rosen CJ, Heiniluoma KM, Hogue MM, Morrison A, et al. Tamoxifen and estrogen lower circulating lipoprotein(a) concentrations in healthy postmenopausal women . Arterioscler Thromb . 1994;14:1586–1593
  15. Gonbert S, Malinsky S, Sposito AC, Laouenan H, Doucet C, Chapman MJ, et al. Atorvastatin lowers lipoprotein(a) but not apolipoprotein(a) fragment levels in hypercholesterolemic subjects at high cardiovascular risk . Atherosclerosis . 2002;48:1454–1459
  16. Akaike M Azuma H, Kagawa A, Matsumoto K, Hayashi I, Tamura K, Nishiuchi T, et al. Effect of aspirin treatment on serum concentrations of lipoprotein(a) in patients with atherosclerotic diseases . Clin Chem . 2002;48:1454–1459
  17. Bosch T . State of the art of lipid apheresis . Artificial Organs . 1996;20:292–295
  18. Thompson GR , HEART-UK LDL Apheresis Working Group  . Recommendations for the use of LDL apheresis . Atherosclerosis . 2008;198(2):247–255
  19. Borberg H . 26 Years of LDL - Apheresis: A review of experience . Transfus Apher Sci . 2009 Aug;41(1):49–59 Epub 2009 Jun 25.
  20. Bosch T, Schmidt B, Kleophas W, Gillen C, Otto V, Passlick-Deetjen J, et al. LDL Hemoperfusion-A New Procedure for LDL Apheresis: First Clinical Application of an LDL Adsorber Compatible with Hman Whole Blood . Artificial Organs . 1997;21(9):977–982
  21. Dräger LJ, Julius U, Kraenzle K, Schaper J, Toepfer M, Zygan K, et al. DALI – the first human whole blood low-density lipoprotein and lipoprotein (a) apheresis system in clinical use: procedure and clinical results . Eur. J. Clin. Invest. . 1998;28:994–1002
  22. Stefanutti C , Di Giacomo S , Vivenzio A . Comparison between different techniques of LDL-apheresis . Int. J. Art. Organs . 1997;21(S–6):66–71
  23. Carsten Otto , Jutta Berster , Bärbel Otto , Klaus G . Parhofer: Effects of Two Whole Blood Systems (DALI and Liposorber D) for LDL Apheresis on Lipids and Cardiovascular Risk Markers in Severe Hyper- cholesterolemia . Journal of Clinical Apheresis . 2007;22:301–305
  24. Borberg H . Comparison of different Lp (a) elimination techniques: A retrospective evaluation . Transfus Apher Sci . 2009 Aug;41(1):61–65 Epub 2009 Jun 21.
  25. Thompson GR, Maher VM, Matthews S Kitano Y, Neuwirth C, Davies G, Rees A, et al. The familial hyper choles terolaemia regression study: a randomised trial of low-density-lipoprotein apheresis . Lancet . 1995;345:811–816
  26. Kroon AA, Aengevaeren WR, van der Werf T, Uijen GJ, Reiber JH, Bruschke AV, et al. LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis . Circulation . 1996;93:1826–1835
  27. Jaeger BR, Richter Y, Nagel D, Heigl F, Vogt A, Roeseler E, et al. Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events . Nature Clinical Practice Cardiovascular Medicine . 2009;6(3):229–239
  28. Stefanutti C, Vivenzio A, Di Giacomo S, Mazzarella B, Ferraro PM, Abbolito S. Treatment of symptomatic hyperLp(a)lipidemia with LDL-apheresis vs usual care Transfusion and Apheresis Sci 2009; DOI:10.1016/j.transci.2009.10.003.
  29. Stefanutti C and the Italian Multicenter Study on Low-Density Lipoprotein Apheresis Working Group: Italian Multicenter Study on Low-density Lipoprotein Apheresis: Retrospective Analysis (2007). Therapeutic Apheresis and Dialysis 2009; Published Online: Jul 17 2009 3:00AM DOI: 10.1111/j.1744-9987.2009.00704.x

PII: S1567-5688(09)71819-7

doi: 10.1016/S1567-5688(09)71819-7

Atherosclerosis Supplements
Volume 10, Issue 5 , Pages 89-94 , 29 December 2009

Article Tools